B
Bull
Bull · 25%EVH
$10.23
Scenario price
$4.570
-0.282 (-6.16%)At close
Loading chart…
- High
- 4.950
- Open
- 4.890
- VWAP
- 4.69
- Volume
- 2.08M
- Mkt Cap
- 2.30B
- Low
- 4.550
- Amount
- 9.75M
- EV/EBITDA, TTM
- 20.50
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
AI analysis of Evolent Health Inc (EVH)
BuyEvolent Health Inc is a good buy right now due to its current price of $4.57, which is significantly below the average analyst price target of $6.5, indicating a potential upside of approximately 42%. Additionally, the stock has shown a strong momentum with a 5-day change of +13.12% and a 20-day change of +23.85%. However, investors should be cautious of the company's high net debt-to-EBITDA ratio of 7x, which poses a risk if market conditions worsen.
Analyst Ratings (13)
+104.16% upside
Buy
13 Buy
0 Hold
0 Sell
Current: 4.57
Low
5.00
Average
9.33
High
16.00
Citi
Buy
$6
2026-08-10
Citi
2026-08-10
Price Target
$6
Buy
Canaccord
Buy
$6
2026-08-10
Canaccord
2026-08-10
Price Target
$6
Buy
TD Cowen
Buy
$5
2026-07-28
TD Cowen
2026-07-28
Price Target
$5
Buy
Citi
Neutral
—
2026-07-23
Citi
2026-07-23
Price Target
—
Neutral
Canaccord
Buy
$7
2026-07-21
Canaccord
2026-07-21
Price Target
$7
Buy
Valuation Metrics
The current forward P/E ratio for Evolent Health Inc (EVH) is 8.62, compared to its 5-year average forward P/E of 73.10.
Alphio AI Price Scenarios for EVH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding EVH
Events Timeline
News
9.510-09PRnewswireEvolent Health to Release Q3 2026 Financial Results on November 5
7.509-21PRnewswireExpanded Partnership Enhances Language Access Across Evolent's Network
7.509-21NewsfilterEvolent Expands Partnership with TransPerfect to Enhance Language Access
6.508-16Yahoo FinanceHealthcare Stock Investment Opportunities and Risks Analysis
2.008-13NASDAQ.COMEvolent Health (EVH) Q2 2026 Earnings Call Transcript
EVH FAQ — answered by Alphio AI
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner. It operates in the Healthcare sector (SERVICES-MANAGEMENT SERVICES industry).
Evolent Health Inc is a good buy right now due to its current price of $4.57, which is significantly below the average analyst price target of $6.5, indicating a potential upside of approximately 42%. Additionally, the stock has shown a strong momentum with a 5-day change of +13.12% and a 20-day change of +23.85%. However, investors should be cautious of the company's high net debt-to-EBITDA ratio of 7x, which poses a risk if market conditions worsen.
13 analysts cover EVH: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.